Effect of diazepam on the efficacy of dual-phase FDG PET imaging [1]

European Journal of Nuclear Medicine and Molecular Imaging

Volumn 33, Issue 2, 2006, Pages 228-229

  Zhuang, Hongming ^a   Hustinx, R ^b   Alavi, A ^c  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b UNIVERSITY OF LIÈGE   (Belgium)

^c HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DIAZEPAM; FLUORODEOXYGLUCOSE F 18;

COMPUTER ASSISTED EMISSION TOMOGRAPHY; DIAGNOSTIC ACCURACY; DRUG EFFICACY; ENZYME ACTIVITY; ENZYME INHIBITION; GLUCOSE TRANSPORT; HUMAN; INSULIN RELEASE; LETTER; NASOPHARYNX CARCINOMA; TUMOR CELL;

ADMINISTRATION, ORAL; CARCINOMA; DIAZEPAM; DRUG INTERACTIONS; FLUORODEOXYGLUCOSE F18; GLUCOSE TRANSPORT PROTEINS, FACILITATIVE; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; LYMPHATIC METASTASIS; NASOPHARYNGEAL NEOPLASMS; NEOPLASM METASTASIS; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; REPRODUCIBILITY OF RESULTS;

EID: 31444456758     PISSN: 16197070     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00259-005-1957-y     Document Type: Letter

References (13)

1. Yen TC, Chang YC, Chan SC, Chang JTC, Hsu CH, Lin KJ, et al. Are dual-phase F-18-FDG PET scans necessary in nasopharyngeal carcinoma to assess the primary tumour and locoregional nodes? Eur J Nucl Med Mol Imaging 2005;32:541-8
2. Boerner AR, Weckesser M, Herzog H, Schmitz T, Audretsch W, Nitz U, et al. Optimal scan time for fluorine-18 fluorodeoxyglucose positron emission tomography in breast cancer. Eur J Nucl Med 1999;26:226-30
3. Kubota K, Itoh M, Ozaki K, Ono S, Tashiro M, Yamaguchi K, et al. Advantage of delayed whole-body FDG-PET imaging for tumour detection. Eur J Nucl Med 2001;28:696-703
4. Hustinx R, Smith RJ, Benard F, Rosenthal DI, Machtay M, Farber LA, et al. Dual time point fluorine-18 fluorodeoxyglucose positron emission tomography: a potential method to differentiate malignancy from inflammation and normal tissue in the head and neck. Eur J Nucl Med 1999;26:1345-8
5. Zhuang H, Pourdehnad M, Lambright ES, Yamamoto AJ, Lanuti M, Li PY, et al. Dual time point F-18-FDG PET imaging for differentiating malignant from inflammatory processes. J Nucl Med 2001;42:1412-7
6. Demura Y, Tsuchida T, Ishizaki T, Mizuno S, Totani Y, Ameshima S, et al. F-18-FDG accumulation with PET for differentiation between benign and malignant lesions in the thorax. J Nucl Med 2003;44:540-8
7. Kubota K, Yokoyama J, Yamaguchi K, Ono S, Qureshy A, Itoh M, et al. FDG-PET delayed imaging for the detection of head and neck cancer recurrence after radio-chemotherapy: comparison with MRI/CT. Eur J Nucl Med Mol Imaging 2004;31:590-5
8. Lai CH, Huang KG, See LC, Yen TC, Tsai CS, Chang TC, et al. Restaging of recurrent cervical carcinoma with dual-phase F-18 fluoro-2-deoxy-D-glucose positron emission tomography. Cancer 2004;100:544-52
9. Klepper J, Florcken A, Fischbarg J, Voit T. Effects of anticonvulsants on GLUT1-mediated glucose transport in GLUT1 deficiency syndrome in vitro. Eur J Pediatr 2003;162:84-9
10. Oudard S, Miccoli L, Dutrillaux B, Poupon MF. Targeting the gene of glucose metabolism for the treatment of advanced gliomas. Bull Cancer 1998;85:622-6
11. Shaheen AA, Hamdy MA, Kheir-Eldin AA, Lindstrom P, el-Fattah AA. Effect of pretreatment with vitamin E or diazepam on brain metabolism of stressed rats. Biochem Pharmacol 1993;46:194-7
12. Miccoli L, Poirson-Bichat F, Sureau F, Bras Goncalves R, Bourgeois Y, Dutrillaux B, et al. Potentiation of lonidamine and diazepam, two agents acting on mitochondria, in human glioblastoma treatment. J Natl Cancer Inst 1998;90:1400-6
13. Chevassus H, Mourand I, Molinier N, Lacarelle B, Brun JF, Petit P. Assessment of single-dose benzodiazepines on insulin secretion, insulin sensitivity and glucose effectiveness in healthy volunteers: a double-blind, placebo-controlled, randomized cross-over trial. BMC Clin Pharmacol 2004;4:3